YK-11 Overview

Why We Need It

YK-11 is a synthetic myostatin inhibitor and selective androgen receptor modulator (SARM) first identified in 2011. It promotes extreme muscle hypertrophy by activating androgen receptors and inhibiting myostatin, a protein that limits muscle growth. While promising, YK-11 remains investigational with no FDA-approved uses.

Mechanism of Action

1. YK-11 works by dual action on two powerful muscle-building pathways:
2. Androgen Receptor Activation
3. Binds to androgen receptors in muscle tissue to stimulate muscle protein synthesis.
4. Activates anabolic pathways like mTOR, enhancing muscle growth and recovery.
5. Myostatin Inhibition
6. Suppresses myostatin, a negative regulator of muscle growth, allowing for supraphysiological
7. hypertrophy beyond genetic limits.
8. This dual mechanism makes YK-11 uniquely positioned to maximize muscle building while
9. supporting bone density through enhanced osteogenic differentiation.

Functions and Benefits

- Inhibits myostatin, unlocking muscle growth potential
- Activates androgen receptors, stimulating protein synthesis
- Enhances lean muscle mass and physical strength
- Improves bone density and skeletal strength
- Accelerates muscle recovery and reduces catabolic breakdown
- May improve muscular endurance and regeneration



Medical-Grade Dosing

Dose: 5–15 mg per day
Frequency: Once or split twice daily (half-life ~6–8 hours)
Cycle Duration: 4–8 weeks
Post-Cycle Therapy (PCT): Strongly recommended; Clomid or Nolvadex advised
Liver Support: NAC 600–1,200 mg/day or TUDCA 250 mg/day recommended during cycle

Pharmacology and Bioavailability

- Poor water solubility; best delivered in oral suspension or liposomal form
- Metabolized in the liver; liver enzyme monitoring advised
- Chemically synthesized, not naturally occurring
- Research-use only with no approved human applications

Administration Guidelines

- Take with meals to improve absorption
- Monitor hormone levels (Testosterone, LH, FSH) pre- and post-cycle
- Consider gradual tapering or bridging strategies for HPTA recovery post-cycle

Conclusion

YK-11 is a powerful anabolic research compound combining androgen receptor activation with myostatin inhibition, providing maximum muscle growth potential and bone strengthening benefits. Due to its experimental status and potential for hormonal disruption, responsible use requires professional oversight, liver monitoring, and proper post-cycle management.